Brought to you by 
Series B brings in $45.5mm for Akero
19 Jun 2019
Executive Summary
Akero Therapeutics Inc. raised $45.5mm through a Series B round led by Janus Henderson Investors, which was joined by other first-time backers Redmile Group, Boxer Capital of Tavistock Group, Cormorant Asset Management, BVF Partners, Rock Springs Capital, and LifeSci Venture Partners, and returning shareholders Apple Tree Partners, Atlas Venture, venBio Partners, and Versant Ventures. According to the Form D filing, 20 investors participated. The company will use the proceeds to move its lead program AKR001 (licensed from Amgen in June) through Phase II trials for nonalcoholic steatohepatitis, to scale manufacturing, and expand its metabolic disease pipeline.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B brings in $45.5mm for Akero
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice